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Abstract
Purpose: A delay in encountering the cognate antigen while
in the circulation, and the suboptimal costimulation received at
the tumor site are key reasons for the limited activity of chimeric
antigen receptor–redirected T cells (CAR-T) in solid tumors. We
have explored the benefits of incorporating the IL15 cytokine
within the CAR cassette to provide both a survival signal before
antigen encounter, and an additional cytokine signaling at the
tumor site using a neuroblastoma tumor model.
Experimental Design: We optimized the construct for the
CAR specific for the NB-antigen GD2 without (GD2.CAR) or
withIL15(GD2.CAR.15).Wethencomparedtheexpansion,phe-
notype, and antitumor activity of T cells transduced with these
constructs against anarrayofneuroblastomacell lines in vitroand
in vivo using a xenogeneic metastatic model of neuroblastoma.
Results: We observed that optimized GD2.CAR.15-Ts
have reduced expression of the PD-1 receptor, are enriched
in stem cell–like cells, and have superior antitumor activity
upon repetitive tumor exposures in vitro and in vivo as
compared with GD2.CAR-Ts. Tumor rechallenge experi-
ments in vivo further highlighted the role of IL15 in promot-
ing enhanced CAR-T antitumor activity and survival, both in
the peripheral blood and tissues. Finally, the inclusion of the
inducible caspase-9 gene (iC9) safety switch warranted
effective on demand elimination of the engineered GD2.
CAR.15-Ts.
Conclusions:Our results guide new therapeutic options for
GD2.CAR-Ts in patients with neuroblastoma, and CAR-T
development for a broad range of solid tumors.
Introduction
Neuroblastoma is the most common extracranial tumor of
childhood (1). Because children with high-risk neuroblastoma
continue to have poor outcome despite intensive chemotherapy
regimens, new treatment strategies are required (2, 3). The dis-
ialoganglioside GD2, which is consistently expressed in neuro-
blastoma tumor cells with restricted expression in normal tissues,
represents the target of choice for immunotherapy in neuroblas-
toma, through either a specific mAb (Ch14.18, dinutuximab) or,
more recently, chimeric antigen receptor engineered T cells (GD2.
CAR-Ts) (3–6).
In the first clinical studywithGD2.CAR-Ts, the specific scFvwas
derived from the murine 14.G2a mAb coupled with the z-chain
endodomain (first-generation CAR), and engrafted in Epstein–
Barr virus–specificCTLs (5, 6). In the second clinical trial, the same
CAR was modified to encode two costimulatory endodomains in
tandem (CD28 andOX40) (third-generation CAR) and expressed
in polyclonal T lymphocytes (4). Both studies showed that infu-
sions of GD2.CAR-Ts were well tolerated, even when combined
with conditioning regimens to lymphodeplete the host, and
promoted some objective clinical responses (4–6).
However, response rates in patientswith neuroblastoma receiv-
ingGD2.CAR-Ts remain significantly inferior to those observed in
patients with acute lymphoblastic leukemia treated with CD19-
specific CAR-Ts (7). It is also evident that, although the inclusion
of costimulatory endodomains like CD28 or 4-1BB in the CD19-
specific CAR is necessary and sufficient to achieve clinical
responses (7–11), CAR costimulation is not equally effective in
neuroblastoma (4). Furthermore, although the expansion of
CD19-specific CAR-Ts in the peripheral blood correlates with
clinical responses (7), increases of GD2.CAR-Ts in the peripheral
blood, even when these cells are infused in lymphodepleted
patients, do not promote better antitumor responses (4). We
speculated that, despite homeostatic expansion in peripheral
blood, in contrast to CD19-specific CAR-Ts, GD2.CAR-Ts do not
promptly receive the costimulation required for full activation
while in the circulation, as they do not engage their cognate
antigen. Furthermore, when GD2.CAR-Ts reach the tumor site,
the costimulation provided through the signaling moieties of the
CAR remains suboptimal to achieve complete elimination of
tumor cells due to local inhibitory/suppressive factors. We
observed here that the inclusion of the IL15 cytokine within the
CAR cassette is beneficial for GD2.CAR-Ts by promoting both
enhanced survival in the absence of the cognate antigen, and
prolonged antitumor activity.
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The neuroblastoma cell lines IMR-32, LAN-1, and SKNLP were
purchased fromATCC,while the CHLA255 cell linewas described
previously (12). Cells weremaintained in RPMI1640 supplemen-
tedwith 10%FBS and 2mmol/L L-glutamine (Invitrogen). Tumor
cell lines were transduced with a gamma retroviral vector encod-
ing the enhanced GFP (eGFP) or the Firefly-luciferase (FFLuc)
genes as described previously (13). Cells were routinely (month-
ly) screened for the presence ofMycoplasma and expression of the
GD2 antigen and kept in culture for less than 3 consecutive
months, after which aliquots from the original expanded vial
were used.
Plasmid and retrovirus construction
The cassette encoding the GD2-specific scFv (scFv14G2a), the
CD8a stalk and transmembrane domain, the CD28 intracellular
domain and CD3z chain was cloned into the SFG backbone
(GD2.CAR). The scFv14G2a was previously identified (14) and
used in clinical studies (4–6). We modified this scFv14G2a by
removing 16 amino acids from the COOH-region of the VH
(AKTTPPSVYGRVYVSS). Indeed, when we aligned the previously
used VH sequence into the IGBLAST NCBI database, these 16
amino acids, which belong to the CDR3-IMGT (germline) of the
VH, exceeded the alignment of the VH sequence reported in the
dataset. Furthermore, two versions of the scFv14G2a were pro-
duced by conserving the previously used 9-aminoacid linker (SL)
between the VL and VH fragments or including a 20-aminoacid
linker (LL). We then generated vector cassettes encoding the CAR
in combination with the IL-15 cdna (GD2.CAR.15) using a 2A-
sequence peptide (15). In a third vector, we also cloned the
inducible caspase-9 suicide gene (16) into the GD2.CAR.15 using
a second 2A-sequence peptide (iC9.GD2.CAR.15). Finally, for
selected experiments, the scFv14G2a in the iC9.GD2.CAR.15
vector was swapped with the CD19-specific scFv (17) to
obtain the iC9.CD19.CAR.IL-15 vector. Vectors encoding the
Firefly-luciferase (FFluc) and the fusion protein GFP have
been previously described (13). The full-length human PD-L1
(accession_NM_014143.4) was PCR amplified, cloned into the
retroviral vector SFG and used to transduce the CHLA255 tumor
cell line to generate tumor cells constitutively expressing high
levels of PD-L1 (CHLA255-PD-L1þ). Transient retroviral super-
natants were produced as previously described (13). For GMP
translation and validation studies a clinical grade packaging cell
line was generated by using the PG13 packaging cell line (gibbon
ape leukemia virus pseudotyping packaging cell line; CRL-10686,
ATCC) as previously described (5). We used the highest titer
clone to establish the master cell bank as recommended by FDA
guidelines.
Generation of CAR-Ts
Peripheral blood mononuclear cells (PBMC) were isolated
from buffy coats (Gulf Coast Regional Blood Center) using
Lymphoprep (Accurate Chemical and Scientific Corporation).
PBMCs were then activated using 1 mg/mL immobilized CD3
(Miltenyi Biotec) and CD28 (BD Biosciences) mAbs. After 3 days,
cells were transduced with retroviral supernatants and expanded
in complete medium (45% RPMI1640 and 45% Click's medium,
10% FBS, and 2 mmol/L GlutaMAX) supplemented with IL7
(10 ng/mL, PeproTech) and IL15 (5 ng/mL, PeproTech) and
expanded by feeding them every 3 to 4 days with fresh complete
media and cytokines, as described previously (18–20).
Western blot analysis
T-cell lysateswere resuspended in 2 Laemelli Buffer (Bio-Rad)
in reducing (with b-mercaptoethanol) or nonreducing (without
b-mercaptoethanol) conditions. All lysates were separated in 4%
to 15% SDS-PAGE gels and transferred to polyvinylidene diflour-
idemembranes (all Bio-Rad). Blots were probed for humanCD3z
Ab (Santa Cruz Biotechnology) diluted 1:1,000 in TBS-Tween/5%
skimmilk.Membraneswere then incubatedwithHRP-conjugated
goat a-mouse or goat a-rabbit IgG (both Santa Cruz Biotechno-
logy) at a dilution of 1:3,000 and imaged using the ECL Substrate
Kit on a ChemiDoc MP System (both BioRad) according to the
manufacturer's instructions.
Coculture experiments
eGFP-transduced tumor cells were plated in 24-well plates at a
concentration of 0.25 or 0.5  106 cells/well the day before the
addition of T cells, in the absence of cytokines. Different effector
cells to target cells (E:T) ratios were used (1:1, 1:5 and 1:10). For
the repetitive coculture experiments, T cells and eGFP-tagged
neuroblastoma cells were cocultured at the E:T ratio of 1:1 or
1:5. At day 3, all cells were transferred into a new well and seeded
with 0.25  106 neuroblastoma cells. T cells and neuroblastoma
cells were quantified by flow cytometry after 4 cycles based on
CD3 and GFP expression, respectively. Supernatant were also
collected for cytokine measurements after each cycle. For each
experiment, nontransduced T cells were used as a negative control
(Ctrl-Ts).
Carboxyfluorescein succinimidyl ester-based proliferation
assay
CAR-Ts and control T cells were labeled with carboxyfluores-
cein succinimidyl ester (CFSE; Invitrogen) and plated in the wells
precoatedwith orwithout the 1A7 antibody (0.5mg/well). Onday
5, cells were collected and analyzed for CFSE dilution by flow
cytometry.
Translational Relevance
Response rates in patients with neuroblastoma receiving
GD2.CAR-Ts remain significantly inferior to those observed in
patients with acute lymphoblastic leukemia treated with
CD19.CAR-Ts. This is consequent to the limited GD2.CAR-Ts
survival in the circulation and at the tumor site. To solve these
issues, we have incorporated IL15 within the CAR construct to
generate GD2.CAR.15-Ts. These cells enriched in centralmem-
ory/stem cell–like cells and expressing PD-1 at lower level
promoted superior antitumor activity, expansion, and survival
in vitro and in vivo. To improve the safety of the GD2.
CAR.15-Ts, we have incorporated the iC9 safety switch gene
and validated the feasibility of generating T-cell products
incorporating the three genes in accordance with good
manufacturing practice. Our discoveries guide an efficient and
safe therapeutic option of GD2.CAR-Ts in patients with neu-
roblastoma, and are highly relevant for the development of
CAR-T for solid tumors in general.
bled at specific intervals (10–15 days, as per UNC-IACUC guide-
lines) to measure cytokines in the plasma and frequency of CAR-
Ts. Mice were followed after CAR-Ts treatment and euthanized
when tumor growth caused discomfort as per veterinarian's
recommendation. At the time of euthanasia, blood, spleen, liver,
and bonemarrowwere isolated and analyzed to detect CAR-Ts. To
assess differences in response to continuous exposure to tumor
cells, we performed tumor rechallenge experiments, where tumor-
bearing mice were further injected intravenously with 3  106
CHLA255 cells labeled with FFLuc at day 7 and 14 or at day 28
after CAR-T treatment. In selected experiments, tumor-bearing
mice received intraperitoneally the PD-1–blocking antibody
(clone EH12.2H7, BioLegend; 200 mg/mouse every 4 days) start-
ing from the day before the CAR-Ts infusion. In some experi-
ments, mice were engrafted with the FFLuc CHLA255 tumor cell
line genetically engineered to express high levels of PD-L1
(CHLA255-PD-L1þ cells) in the attempt to further promote T-cell
exhaustion in vivo. To ensure the function of the suicide gene, 10
106 FFLuc-tagged CAR-Ts were injected intravenously into NSG
mice. T-cell expansion was then tracked by in vivo imaging
measuring T-cell BLI. Mice were randomized to receive vehicle
or CID (AP20187, 50 mg/mouse), and then imaging was per-
formed to evaluate the elimination of T cells. In selected experi-
ments, mice were challenged with 3 106 CHLA255 cells, 4 days
after CID/vehicle treatment.
Statistical analysis
ANOVAwithBonferroni correction and the two-sidedunpaired
t test were used for comparison of 3 or more groups, or 2 groups,
respectively, as stated in the figure legends. Mixed model ANOVA
was applied to compare tumor growth in different groups ofmice.
Survival curves were plotted using the Kaplan–Meiermethod, and
the differences in the survival between groups were assessed by
log-rank test. Data are presented asmean SD or SEM as stated in
the figure legends. Statistical significance was defined at P < 0.05.
Statistical analysis was performed with Prism 5 (GraphPad
Software).
Results
T lymphocytes transduced with a modified GD2.CAR
expressing the IL15 retain a central memory/stem cell–like
phenotype and show lower expression of inhibitory receptors
We first reevaluated the structure of the GD2.CAR generated
using the scFv derived from the 14G2a mAb. Specifically, we
compared the previously constructed GD2.CARs encoding the
CD28endodomain (24)with amodifiedGD2.CAR, characterized
by a shortened VH sequence and containing the hinge and
transmembrane domain of human CD8a instead of the
Ig-derived hinge and CD28 transmembrane domain, and found
that the new optimized GD2.CAR had superior activity in in vitro
experiments (Supplementary Fig. S1A–S1F), and reduced self-
dimerization (Supplementary Fig. S1G). We then generated two
cassettes, encoding either the optimized GD2.CAR alone or
the GD2.CAR in combination with IL15 (GD2.CAR.15) using a
2A-sequence peptide (Fig. 1A). CAR expression (Fig. 1B) and
expansion (Fig. 1C) of T cells transduced with either GD2.CAR
or GD2.CAR.15 vectors were similar. Phenotypically both GD2.
CAR-Ts and GD2.CAR.15-Ts contained similar amounts of CD4þ
and CD8þ T cells (Supplementary Fig. S2A). In contrast, GD2.
CAR.15-Ts contained higher frequency of central memory T cells
Side population staining by Hoechst dye
Cells were incubated in Hank's Balanced Salt Solution 
(Life Technologies) containing 2% FBS, 10 mmol/L HEPES (Life 
Technologies), and either 10 mg/mL Hoechst 33342 (Sigma-
Aldrich) for 90 minutes at 37C. Cells were then washed with 
ice-cold HBSS and labeled with CD3-APC for flow cytometry 
analysis. To detect the side population (SP) cells, Hoechst 33342 
samples were excited using a 355 nm UV laser on a LSRII/Fortessa 
flow cytometer (BD Biosciences; refs. 21, 22).
Cytokine measurements
Culture supernatants were collected after 24 hours of coculture 
to measure the release of IL2, IFNg , and TNFa, and after 72 hours 
for IL15, using specific ELISA (R&D Systems, Inc). Plasma 
obtained from mice was analyzed for the presence of human 
cytokines using the Bio-Plex Pro Human Cytokine 8-plex Assay 
(Bio-Rad) or Human High Sensitivity Cytokine B Premixed Mag 
Luminex Performance Assay (R&D Systems) following the man-
ufacturer's instructions. Data were collected and analyzed using 
the Lumina-200 System and the Bio-Plex Manager 6.1 software 
(Bio-Rad).
Activation of the suicide gene
The B/B homodimerizer AP20187, a chemical inducer of 
dimerization drug (CID; Clontech Laboratories), was added at 
50 nmol/L to T-cell cultures and induction of apoptosis evaluated 
24 hours later using Annexin-V/7AAD staining (BD Biosciences) 
and FACS analysis (16).
Immunophenotyping
Cells were acquired using the BD FACS Fortessa (BD Bio-
sciences) and analyzed using the FlowJo Software (Tree Star). 
mAbs specific for GD2, CD45, CD3, CD8, CD45RA, CD45RO, 
PD-1, CCR7, CD45, LAG-3, TIM-3, TIGIT, CTLA-4, CD25, CD69, 
active caspase-3, and granzyme B were obtained from BD Bios-
ciences. To detect the GD2.CAR expression in transduced T cells, 
we used the 1A7 anti-idiotype mAb specific for the 14G2a.scFv 
and PE or APC-conjugated rat anti-mouse secondary mAbs (BD 
Biosciences; ref. 5). In selected experiments, counting beads 
(Count Bright, Invitrogen) were added following the manufac-
turer's instructions. For the intracellular staining, cells were 
stained with Zombie dye and surface antibodies, including 
CD3 and GD2, washed, fixed, and permeabilized with Cytofix/
Cytoperm (BD Biosciences), and then stained with active caspase-
3 in  1 permeabilization buffer, following the manufacturer's 
instructions.
Xenogeneic neuroblastoma models
Mouse experiments were performed in accordance with the 
University of North Carolina (UNC, Chapel Hill, NC) animal 
husbandry guidelines according to protocols approved by the 
UNC institutional animal care and use committee. For these 
studies, 6- to 8-week-old female and male NSG mice (NOD. 
Cg-Prkdcscid IL2rgtm1Wj1/SzJ, UNC Animal Studies Core Facility) 
received intravenously via tail injection 2  106 CHLA255 cells 
labeled with FFLuc. Tumor engraftment was measured as biolu-
minescence signal intensity (BLI) and expressed as total flux (p/s) 
using the in vivo IVIS imaging (Caliper Life Science; ref. 23). Two 
weeks after tumor engraftment, mice received intravenously either 
2  106, 5  106, or 10  106 control-Ts (Ctrl) or CAR-Ts. No 
exogenous cytokines were administered to the mice. Mice were
(CD45ROþCCR7þ; 15%  7% vs. 7%  3%, P < 0.01) and stem
cell–like T cells (CD45RAþCCR7þ; 25% 11% vs. 6% 2%, P <
0.001) thanGD2.CAR-Ts (Fig. 1D). Furthermore,GD2.CAR.15-Ts
showed lower constitutive expression of PD-1 as compared with
GD2.CAR-Ts in both central memory (25%  20% vs. 39% 
17%, P < 0.001) and stem cell–like T cells (8%  11% vs. 17% 
14%, P < 0.01; Fig. 1E; Supplementary Fig. S2B). Downregulation
of PD-1 in GD2.CAR.IL15-Ts was confirmed at the transcription
level (Supplementary Fig. S2C). In GD2.CAR.IL15-Ts, we also
observed low expression of another inhibitory receptor, namely
LAG-3 (Supplementary Fig. S2D), while the activation markers
CD25 and CD69 were equally expressed in GD2.CAR-Ts and
GD2.CAR.IL15-Ts (Supplementary Fig. S2E). Susceptibility to
activation induced cell death (AICD) was also comparable
between GD2.CAR-Ts and GD2.CAR.15-Ts (Supplementary
Fig. S2F). Overall these data suggest that the low expression
of PD-1 and LAG-3 in GD2.CAR.IL15-Ts does not reflect
lower activation but rather a superior fitness. These data were
corroborated in experiments showing that GD2.CAR.15-Ts
proliferated and persisted longer in the absence of exogenous
cytokines or antigen support in vitro (Supplementary Fig. S2G)
and in vivo (Supplementary Fig. S3A and S3B), mimicking the
advantage they will have in the circulation before engaging
tumor cells.
GD2.CAR.15-Ts have improved antitumor activity and
expansion upon antigen exposure in vitro
We cocultured GD2.CAR-Ts and GD2.CAR.15-Ts with four
neuroblastoma cell lines (including MYCN-amplified neuroblas-
toma cells) at an E:T ratio of 1:1 (Supplementary Fig. S4A). Both
GD2.CAR-Ts and GD2.CAR.15-Ts efficiently eliminated tumor
cells (Fig. 2A and Supplementary Fig. S4B), including putative
tumor stem cells identified as SP cells (Supplementary Fig. S4C).
However, GD2.CAR.15-Ts proliferated significantly better in
response to all neuroblastoma cell line tested (Fig. 2B). IL15 was
detectable in the supernatant of cocultures with GD2.CAR.15-Ts,
while no significant differences were observed for other cytokines,
including IL2, TNFa, and IFNg or granzymeB release as compared
with GD2.CAR-Ts (Fig. 2C; Supplementary Fig. S4D and S4E).
Moreover, as observed during the in vitro expansion with cyto-
kines, without antigen stimulation, GD2.CAR.15-Ts showed low-
er expression of PD-1 (Fig. 2D) and LAG-3 (Supplementary
Fig. S4F) upon coculture with neuroblastoma cells as compared
with GD2.CAR-Ts. Target cells showed the same level of cleaved
caspase-3, which is another marker of apoptosis, 24 hours post
coculture (Supplementary Fig. S4G), indicating similar kinetic of
cytotoxic activity of GD2.CAR-Ts and GD2.CAR.IL15-Ts. Remark-
ably, GD2.CAR.15-Ts showed sustained antitumor activity in
stress coculture experiments (25) inwhich T cells were repetitively
Figure 1.
Expression of GD2.CAR in activated T cells. A, Schematic representation of retroviral vectors encoding GD2.CAR with the CD28 endodomain with or without IL15.
B, Flow cytometry histograms showing GD2.CAR expression in activated T cells for one representative experiment (left), and summary of all donors (right graph;
n¼ 12). Nontransduced T cells or mock vector T cells were used as a control. C, CAR-Ts expansion by day 11 after transduction (n¼ 8).D, Representative flow
plots showing CD45RA, CD45RO, CCR7, and PD-1 expression in CAR-Ts collected at day 11 after transduction (left), and summary of all donors (right; n¼ 11).
 , P < 0.01;  , P < 0.001 by two-way ANOVA test. E, PD-1 expression in CD45RA and CCR7 subsets of CAR-Ts at day 11 after transduction (n¼ 15).  , P < 0.01;
 , P < 0.001 by two-way ANOVA test.
exposed to antigen engagement using CHLA255 and LAN-1 cells
(Supplementary Fig. S5A). After 4 cycles of coculture, GD2.
CAR.15-Ts, but not GD2.CAR-Ts, significantly controlled tumor
growth of both CHLA255 and LAN-1 cells (P < 0.05 and P < 0.01,
respectively; Fig. 2E; Supplementary Fig. S5B) and proliferated in
response to repetitive exposure to each respective tumor cell line
(P < 0.01 and P < 0.05, respectively; Fig. 2F). GD2.CAR.15-Ts
continued to produce IL15 after each cycle of stimulation in
Figure 2.
GD2.CAR-Ts producing IL15 have enhanced cytotoxic activity upon repetitive exposure to tumor cells in vitro and produce Th1 cytokines. A and B,Quantification
of residual tumor cells (A) and enumeration of T cells (B) in cocultures of control-Ts (Ctrl), GD2.CAR-Ts, or GD2.CAR.15-Ts with four GD2þ neuroblastoma tumor
cell lines (CHLA255, IMR32, LAN-1, and SKNLP) at the E:T ratio of 1:1 for 7 days (n¼ 4). , P < 0.05;  , P < 0.001 by two-way ANOVA test. C, Cytokine released in
the coculture supernatant by Ctrl-Ts or CAR-Tswhen cocultured with CHLA255 cells at the E:T ratio of 1:1. IL2, TNFa, and IFNg were detected in supernatant
collected 24 hours after the culture, whereas IL15 was detected after 72 hours (n¼ 4).  , P < 0.001 by two-way ANOVA test.D, PD-1 expression of Ctrl-Ts or
CAR-Ts in culture with the indicated target cells at the E:T ratio of 1:1. Quantification of residual tumor cells (E) and enumeration of CAR-Ts (F) after four cycles of
coculture of GD2.CAR-Ts or GD2.CAR.15-Ts with CHLA255 or LAN-1 cells (n¼ 10) at the E:T ratio of 1:1.  , P < 0.05;  , P < 0.01 by two-way ANOVA test.G, IL15
released by GD2.CAR-Ts in response to CHLA255 cells after each cycle (n¼ 3).  , P < 0.05 by two-way ANOVA test.H, PD-1 expression by CAR-Ts after 4 cycles
of coculture with CHLA255 or LAN-1 cells at the E:T ratio of 1:1 (n¼ 6).  , P < 0.01 by two-way ANOVA test.
Figure 3.
Transgenic IL15 enhances antitumor effects of GD2.CAR-Ts in vivo. A, Schematic representation of the metastatic xenograft neuroblastomamodel. NSGmice
were inoculated intravenously via tail injection with 2 106 CHLA255 cells labeled with Firefly-luciferase and two weeks later received T cells intravenously. B–D,
Tumor growth in mice receiving 1 107 Ctrl-Ts or CAR-Ts (B), 5 106 Ctrl-Ts or CAR-Ts (C), or 2 106 Ctrl-Ts or CAR-Ts (D). Each panel shows images and
bioluminescence (BLI) kinetics of tumor growth for each mouse (n¼ 4–5/group).
response to both CHLA255 (Fig. 2G) and LAN-1 (Supplementary
Fig. S5C) cells. IFNg was released by CAR-Ts independently of the
IL15 expression after the second round of stimulation with
CHLA255 cells (Supplementary Fig. S5D), and upon repetitive
antigen exposure, GD2.CAR.15-Ts continued to show lower PD-1
expression as compared with GD2.CAR-Ts (Fig. 2H). As observed
after repetitive exposures to the tumor cells, CD25 and CD69
expression were similar between GD2.CAR-Ts and GD2.CAR.
IL15-Ts (Supplementary Fig. S5E), and similar AICDwasobserved
(Supplementary Fig. S5F). Overall, transgenic expression of IL15
harnessed significantly superior antitumor activity in an antigen-
dependent fashion by promoting sustained T-cell proliferation
after multiple exposures to tumor cells.
GD2.CAR.15-Ts are protective in an in vivo tumor rechallenge
model. We compared the antitumor activity of GD2.CAR-Ts and
GD2.CAR.15-Ts in ametastatic neuroblastomamodel using NSG
mice engrafted with the CHLA255 neuroblastoma tumor cell line
(Fig. 3A). At the time of T-cell infusion mice were randomized
based on the tumor BLI to ensure similar tumor burden between
the experimental groups (Supplementary Fig. S6A). Tumor grew
rapidly in mice treated with Ctrl cells, while GD2.CAR-Ts and
GD2.CAR.15-Ts promoted equal control of tumor growth at day
50when 1 107 T cells/mouse were infused (Fig. 3B). In contrast,
only GD2.CAR.15-Ts succeeded in controlling tumor growth at
day 50 when 5 106 T cells/mouse or 2 106 T cells/mouse were
infused (Fig. 3C and D). The protective effect of GD2.CAR.15-Ts
was even more prominent in tumor rechallenge experiments,
when mice, in addition to the initial tumor burden, received
weekly infusions of neuroblastoma tumor cells (Fig. 4A). GD2.
CAR.15-Ts–treated mice were tumor free >50 days after T-cell
infusion, while tumor growth was evident 2 weeks after the first
tumor rechallenge in mice treated with GD2.CAR-Ts (Fig. 4B–D).
GD2.CAR.15-Ts were detectable in the peripheral blood, and,
consistently with the in vitro data, showed lower PD-1 expression
(Fig. 4E). GD2.CAR.15-Ts were also detected in bone marrow,
liver, and spleen at the time of euthanasia (Fig. 4F) and showed
low PD-1 expression, although in these later stages they were
mostly effector cells (CD45ROþCD45RA–CCR7–; Supplementary
Fig. S6B–S6D). In addition to IFNg , IL15 produced by GD2.
CAR.15-Tswas detectable in the plasma up to day 23 postinfusion
(Fig. 4G), while IL2 and TNFa were below the limit of detection
(Supplementary Fig. S6E). To investigate whether the decreased
PD-1 expression in GD2.CAR.15-Ts protects these cells in vivo
from tumor induced exhaustion, tumor-bearingmicewere treated
with GD2.CAR-Ts or GD2.CAR.15-Ts in combination with the
PD-1–blocking Ab (Supplementary Fig. S7A). PD-1 blockade did
not provide any advantage in mice treated with GD2.CAR.15-Ts,
because these cells show low PD-1 expression (Supplementary
Fig. S7B). However, we also found that PD-1 blockade
did not significantly improve persistence, cytokine release (Sup-
plementary Fig. S7C and S7D), and antitumor activity (Supple-
mentary Fig. S7B) in mice treated with CAR.GD2-Ts. When we
Figure 4.
Transgenic IL15 promotes antitumor activity and persistence of GD2.CAR-Ts in vivo in a rechallenge tumor model. A, Schematic representation of tumor
rechallenge experiments in the metastatic xenograft neuroblastomamodel. After tumor engraftment and T-cell treatment, mice received intravenous tumor
CHLA255 cells labeled with Firefly-luciferase (3 106 cells/mouse) on days 7 and 14. A group of mice infused with CHLA255 cells only was used as a second
control for this model. B, BLI illustrating tumor growth in mice. Arrows indicate the tumor rechallenges. C, BLI kinetic of tumor growth. Each line represents an
individual mouse for the Ctrl (n¼ 5) or CAR-Ts treatment (n¼ 5) and rechallenge group (n¼ 2). Arrows, tumor rechallenges.D, Kaplan–Meier survival curve
showing tumor free survival. Significance was determined by log-rank test (Mantel–Cox). , P¼ 0.0005. E,Quantification of human T cells (CD45þ cells; top)
and CARþPD-1þ cells (bottom) in peripheral blood samples collected at days 7 and 14 after T-cell infusion (n¼ 5).  , P < 0.05;  , P < 0.001 by two-way ANOVA
test. F,Quantification of human T cells (CD45þ cells; top) and CARþPD-1þ cells (bottom) in peripheral blood, bone marrow, liver, and spleen at days 45 to 55 after
T-cell treatment (n¼ 6).  , P < 0.05;  , P < 0.01;  , P < 0.001 by two-way ANOVA test.G, Detection of IL15 (left) and IFNg (right) in plasma samples collected at
days 7, 14, and 23 after T-cell treatment (n¼ 5).  , P < 0.01 by two-way ANOVA test.
short-linker in the GD2-specific scFv with a long-linker (Supple-
mentary Fig. S9C). Although the size of the linker did not
significantly affect the expression and function of the GD2.CAR
in the absence of the iC9 (Fig. 9D–F), the long-linker stabilized the
GD2.CAR expression when the iC9 cdnawas incorporated within
the cassette (iC9.GD2.CAR.15; Supplementary Fig. S10A and
S10B), allowing proper T-cell expansion in vitro (Supplementary
Fig. S10C), and preservation of the same cell subset composition
(Supplementary Fig. S10D). Expanded iC9.GD2.CAR.15-Ts
showed functional activity of all three genes incorporated within
the cassette. Specifically, the inclusion of the iC9 caused cell death
when iC9.GD2.CAR.15-Ts were incubated with 50 nmol/L of the
CID/AP20187 (Supplementary Fig. S10E). Moreover, iC9.GD2.
CAR.15-Ts showed in vitro antitumor activity, proliferative
capacity against CHLA255 or LAN-1 cells comparable with that
of GD2.CAR.15-Ts (Supplementary Fig. S10F and Supplementary
Fig. S11A and S11B), similar pattern of PD-1 expression (Sup-
plementary Fig. S10G and Supplementary Fig. S11C), and similar
release of cytokines (Supplementary Fig. S10H and Supplemen-
tary Fig. S11D). Overall, an optimal design of the GD2.CAR
allowed the functional accommodation of both the IL-15 and
iC9 transgenes.
Using our rechallenge tumor model, we finally assessed in vivo
the antitumor effects of iC9.GD2.CAR.15-Ts (Fig. 5A). Although
tumor BLI rapidly increased in the control group, mice treated
Figure 5.
iC9.GD2.CAR.15-Ts retain the same antitumor activity of GD2.CAR.IL15-Ts in vivo.A, Schematic representation of tumor rechallenge experiments in a metastatic
xenograft neuroblastomamodel. Upon tumor engraftment and T-cell treatment, mice received intravenous tumor CHLA255 cells labeled with Firefly-luciferase
(3 106 cells/mouse) on days 7 and 14. A group of mice infused with CHLA255 cells alone was used as a second control for this model. B, BLI illustrating
tumor growth in mice. Arrows, tumor rechallenges. C, BLI kinetic of tumor growth. Each line represents an individual mouse. Arrows, tumor rechallenge.
D, Kaplan–Meier survival curve showing tumor free survival. Significance was determined by log-rank test (Mantel–Cox).  , P < 0.0001. E,Quantification of
human T cells (CD45þ cells; left) and CD3þCARþ cells (right) in the peripheral blood of treated mice at days 10, 17, and 27 after T-cell infusions (n¼ 5).  , P < 0.01
by two-way ANOVA test.
used CHLA255 cells constitutively expressing PD-L1 (Supplemen-
tary Fig. S8A), GD2.CAR.15-Ts cells continued to control tumor 
growth with or without PD-1 blockade, while a modest advantage 
was observed with PD-1 blockade in mice treated with GD2.CAR-
Ts (Supplementary Fig. S8B–S8D). These data indicate that GD2. 
CAR.15-Ts persist better after tumor clearance and after tumor 
rechallenge, but these effects are not directly correlated with an 
improved resistance to PD-L1 inhibition.
An optimized GD2.CAR construct allows the accommodation 
of the iC9 safety switch, while preserving the functionality of 
IL15
Because of the potential for aberrant T-cell proliferation or 
toxicities in the presence of sustained exposure to IL15, we 
included the iC9 safety switch gene into our construct, to prompt-
ly remove GD2.CAR.15-Ts. Upon inclusion of the iC9 cdna into 
the GD2.CAR.15 cassette, we unexpectedly observed a progressive 
loss of CAR expression when cells were maintained in culture, 
with a consequent reduced antitumor activity in vitro (Supple-
mentary Fig. S9A). This phenomenon was a unique feature of the 
GD2.CAR, as a similar cassette constructed to express the CD19-
specific CAR did not show any significant reduction of the CAR 
expression (Supplementary Fig. S9B). Because the only difference 
in the two scFvs (CD19-specific and GD2-specific) was the size of 
the linker (20 versus 9 amino acids, respectively), we replaced the
with GD2.CAR.15-Ts and iC9.GD2.CAR.15-Ts remained tumor
free by day 40 after rechallenge (Fig. 5B andC). This translated in a
significantly better tumor free survival (P < 0.0001; Fig. 5D). GD2.
CAR.15-Ts and iC9.GD2.CAR.15-Ts showed similar persistence
(Fig. 5E) in mice after infusion, without significant differences in
T-cell composition (Supplementary Fig. S12A). Together, our data
show that the incorporation of the iC9 safety switch into an
optimized GD2.CAR.15 construct remains beneficial in vivo.
To validate the functionality of the iC9 suicide gene,
NSG mice infused intravenously with eGFP-FFLuc labeled
iC9.GD2.CAR.15-Ts were treated with either AP20187 (CID;
50 mg/mouse) or diluent (vehicle; Fig. 6A). While progressively
increasing in mice treated with vehicle, BLI decreased promptly
and remained low after CID administration (Fig. 6B). Similarly,
phenotypic analysis showed that circulating human T cells
almost completely disappeared in CID-treated mice, while
increased in vehicle-treated mice (2%  0.5% vs. 25% 
2%, P < 0.001; Fig. 6C). When we analyzed tissues collected
at the end of the observation period, CAR-Ts were reduced in
CID-treated mice as compared with vehicle-treated mice
(Fig. 6D). Finally, in selected experiments when mice were
rechallenged with tumor cells after CID or vehicle treatment
to reactivate residual T cells, we observed no increase in BLI in
any of the mice that previously received CID (Fig. 6E), which
suggests that the residual CAR-Ts after CID treatment are not
reactivated and thus cannot cause toxicity in vivo.
To further demonstrate the clinical applicability of the pro-
posed approach, we have generated a clinical grade PG13 retro-
viral packaging cell line (20) and produced clinical grade super-
natant. As shown in Supplementary Fig. S13, iC9.GD2.CAR.15-Ts
generated under GMP conditions for clinical use maintained the
same characteristic of those generated in preclinical experiments
ensuring the clinical application of the proposed strategy in
patients with neuroblastoma. The clinical protocol was recently
approved by FDA (IND 18500).
Discussion
GD2.CAR-Ts expressing costimulatory endodomains have
been proven safe in patients with neuroblastoma, but their
antitumor activity remains limited (4), suggesting that additional
preclinical assessment is needed to improve their clinical activity.
Here, we show that modifications of the GD2.CAR structure and
the incorporation of IL15 proved to be key requirements to
enhance antitumor activity without causing on target toxicity.
Our rationale for redesigning GD2.CAR-Ts stems from both
laboratory and clinical observations. Laboratory observations
have highlighted how structural characteristics of CARmolecules,
such as the framework regions of the scFv, and the length and
origin of the hinge, and of the transmembrane endodomain, can
impact the functionality of CAR-Ts (26–28). Specifically for the
scFv of the GD2.CAR obtained from the 14g2a Ab, high tendency
for self-aggregation secondary to interactions within the scFv
framework regions has been described (27). This phenomenon
was associated to an overstimulation of GD2.CAR-Ts, resulting in
the premature exhaustion and reduced antitumor activity of these
Figure 6.
iC9.GD2.CAR.15-Ts can be efficiently eliminated in vivo upon activation of the iC9 gene.A, Schematic representation of the experiments in NSGmice to test the
iC9 activity in vivo. NSGmice were inoculated intravenously with T cells labeled with Firefly-luciferase. Mice received the vehicle or CID via intraperitoneal
injection. In additional experiments, mice were inoculated intravenously with CHLA-255 cells (3 106 cells/mouse) 4 days post CID with the aim to boost CAR-Ts
that may have escaped CID-induced apoptosis. B, Images from representative mice before and after receiving either vehicle or CID as indicated by the arrow.
The graph shows the BLI for of iC9.GD2.CAR.15-Ts in mice treated with either vehicle of CID as indicated by the arrow (n¼ 5). C, Representative flow plots and
summary of human CD45þ and CARþ T cells in the peripheral blood before and after treatment with either vehicle or CID (n¼ 5). D, Summary of human CD45þ
and CARþ T cells in the peripheral blood and organs in the mice treated with either vehicle or CID (n¼ 5).  , P < 0.05;  , P < 0.001 by two-way ANOVA test.
E, Images from representative mice before and after receiving either vehicle or CID (gray arrow), and then rechallenged with tumor cells (black arrow). The graph
shows the BLI of iC9.GD2.CAR.15-Ts in mice treated with either vehicle (n¼ 4) or CID (n¼ 5), and rechallenged with tumor cells.
superior fitness upon multiple exposures to the antigen. The low
expression of PD-1 in GD2.CAR.15-Ts correlated in vivo with lack
of additive effects with PD-1 blockade in controlling the tumor
growth. Of note, in our xenograft model of neuroblastoma, we
also observed that PD-1 blockade did not improve the antitumor
effects of GD2.CAR-Ts that express PD-1, and should be reinvi-
gorated by PD-1 blockade. This outcome may be partially related
to the murine model that does not allow sufficient time to
establish T-cell exhaustion. However, our data resemble the lack
of activity we have previously reported in a pilot clinical trial in
patientswithneuroblastoma (4). Additional studies are needed to
clearly assess if PD-1/PD-L1 blockade can have a positive effect
when combined with GD2.CAR-Ts in neuroblastoma. Neverthe-
less, our data indicate that GD2.CAR-Ts expressing IL15 remain
effective even in a model in which we caused constitutive expres-
sion of PD-L1 in neuroblastoma cells.
Because IL15 is a T-cell growth cytokine, and GD2.CAR.15-Ts
havemore "stem-ness" properties, we incorporated a safety switch
for regulation of potential unwanted and uncontrolled expan-
sion (16, 17, 40, 41). Our data demonstrate that further CAR
construction was required to functionally accommodate these
three genes. However, upon optimization, the final vector cassette
showed functionality in vivo, and we were able to scale up the
production of the CAR-Ts for clinical use. This final step is
important because complex CAR-T engineering strategies often
fail to reach clinical applications due to difficulties in scaling up at
GMP level the results obtained in preclinical experiments.
In conclusion, we demonstrate that GD2.CAR.15-Ts have
functional properties that should provide enhanced antigen-
independent persistence and improved antitumor activity. The
clinical trial in patients with neuroblastoma based on the
proposed strategy will be performed in our institution (IND
18500) and if proven safe and effective, it can have broader
application for targeting solid tumors.
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cells when the CAR contained the CD28 costimulatory signal (27). 
Furthermore, recent evidences indicated that a mutated version of 
the 14g2a.scFv (E101K), which enhances its binding affinity, 
although effective in controlling tumor growth, caused severe 
neurotoxicity in one study (29, 30), but not in another study (31). 
On the other hand, in patients with B-cell–derived malignancies 
the expansion of CD19-specific CAR-Ts in the peripheral blood 
correlates with objective antitumor activity (7). In contrast GD2-
specific CAR-Ts, although expanding in the peripheral blood 
when infused upon lymphodepletion, did not promote signifi-
cant clinical benefits (4). On the basis of these observations for the 
14g2a-derived CAR, we sought to modify structural parts of our 
construct to address intrinsic limitations of the GD2.CAR cassette. 
In addition, we optioned for the inclusion of the IL15 cytokine as a 
survival factor for GD2.CAR-Ts rather than relying simply on PIK3 
and TRAF mediated signaling delivered by the combination of 
CD28 or OX40/4-1BB endodomains upon antigen encoun-
ter (24, 32–35). We reasoned this would provide a cytokine 
signaling that is independent from the costimulation received, 
and from IL2 that is released by CAR-Ts upon antigen engage-
ment (32, 35). We found that structural modifications of the 
GD2.CAR cassette reduced its spontaneous self-aggregation. Fur-
thermore, upon incorporation of IL15, GD2.CAR-Ts retained 
specificity, but showed enhanced expansion and antitumor activ-
ities in vitro, after repeated tumor exposures, and in vivo in our 
innovative xenograft solid tumor model, which includes multiple 
tumor cell rechallenges to recapitulate the high tumor burden in 
patients with solid tumors. Importantly, these effects were 
obtained without evidences of "on target off tumor" toxicities.
Our study highlights that the inclusion of IL15 affords 
GD2.CAR-Ts with other important properties for translation into 
an effective therapy. First, the incorporation of the IL15 within the 
GD2.CAR produced an enrichment of cells with "memory" and 
"stem-cell" like phenotypes. This occurred during the expansion 
culture period, was independent from the specific antigen 
encounter by CAR-Ts, and was significantly superior to that 
already provided by the addition of exogenous IL15 and lL7 
cytokines in the culture (19, 36). Although the mechanistic 
explanation of this phenomenon requires further studies, the 
immediate implication of this observation is that IL15 secreted 
by GD2.CAR-Ts promotes additional effects that are superior to 
those produced by soluble IL15. This may also be critical in 
patients, as the IL15 available in the plasma upon lymphodeple-
tion, despite promoting T-cell expansion, may be inferior to the 
IL15 directly produced and released by GD2.CAR-Ts (4). Exoge-
nous administration of IL15 is accompanied by systemic toxi-
cities (37, 38), and thus we did not formally compare exogenous 
administration versus the endogenous production, as the former 
would not likely be clinically relevant. A membrane-bound form 
of IL15 expressed by CAR-Ts may be also beneficial (39). How-
ever, the incorporation of this gene would compromise the 
expression and function of the CAR, as the construct exceeds the 
cargo capacity of one single vector.
As second advantage, we observed is that GD2.CAR.15-Ts 
had significantly reduced expression of PD-1 and LAG-3 
with and without antigen stimulation, and thus may be less 
susceptible to PD-L1–mediated inhibition, because neuroblasto-
ma cells can express PD-L1, either constitutively or upon exposure 
to IFNg (Supplementary Fig. S8A). The observed low expression of 
PD-1 and LAG-3 in GD2.CAR.15-Ts is not related to a different 
activation status of these cells, but rather suggests their potential
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